APLT Stock Price, Applied Therapeutics Inc Quote, Chart

Market Summary

USD4.18-0.07

Market Closed

-1.65%

APLT Stock Price

View Fullscreen

APLT RSI Chart

APLT Valuation

Market Cap

477.6M

Price/Earnings (Trailing)

-2.47

Price/Sales (Trailing)

47.8

Price/Free Cashflow

-7.12

APLT Price/Sales (Trailing)

APLT Profitability

Return on Equity

-287.64%

Return on Assets

-127.99%

Free Cashflow Yield

-14.05%

APLT Fundamentals

APLT Revenue

Revenue (TTM)

10.0M

APLT Earnings

Earnings (TTM)

-193.6M

Earnings Growth (Yr)

-728.04%

Earnings Growth (Qtr)

-122.77%

Breaking Down APLT Revenue

Last 7 days

-4.8%

Last 30 days

-13.5%

Last 90 days

-22.3%

Trailing 12 Months

176.8%

How does APLT drawdown profile look like?

APLT Financial Health

Current Ratio

1.8

APLT Investor Care

Shares Dilution (1Y)

97.53%

Diluted EPS (TTM)

-1.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	10.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Applied Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 12, 2024	hooks corwin dale	acquired	-	-	300,000	chief commercial officer
Mar 14, 2024	shendelman shoshana	sold	-1,717,110	5.39	-318,573	president and ceo
Mar 14, 2024	perfetti riccardo	sold	-597,234	5.39	-110,804	chief medical officer
Mar 14, 2024	funtleyder leslie d.	sold	-154,839	5.39	-28,727	chief financial officer
Mar 14, 2024	hansard adam	sold	-263,415	5.39	-48,871	chief commercial officer
Dec 28, 2023	chinoporos constantine	acquired	-	-	300,000	see remarks
Dec 21, 2023	hansard adam	acquired	-	-	400,000	chief commercial officer
Dec 21, 2023	perfetti riccardo	acquired	-	-	450,000	chief medical officer
Dec 21, 2023	shendelman shoshana	acquired	-	-	1,540,000	president and ceo
Dec 01, 2023	kanter stacy j.	bought	65,367	2.1789	30,000	-

Which funds bought or sold APLT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	new	-	6,864,600	6,864,600	0.17%
May 16, 2024	COMERICA BANK	unchanged	-	6,900	13,600	-%
May 16, 2024	JANE STREET GROUP, LLC	added	85.44	1,221,480	1,663,360	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	54.39	4,289,560	6,299,690	-%
May 15, 2024	J. Goldman & Co LP	new	-	995,466	995,466	0.03%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-62,601	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-10.32	532,610	1,181,840	0.02%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	new	-	18,018,500	18,018,500	0.03%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-45.75	96,984	1,055,070	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-95.99	-238,859	21,141	-%

Are Funds Buying or Selling APLT?

Are funds buying APLT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own APLT

No. of Funds

Unveiling Applied Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 08, 2024	janus henderson group plc	6.1%	6,414,642	SC 13G
Mar 05, 2024	shendelman shoshana	8.2%	8,646,891	SC 13D/A
Feb 22, 2024	propel bio management, llc	10.5%	8,071,526	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	9.99%	7,877,817	SC 13G/A
Feb 14, 2024	armistice capital, llc	0%	0	SC 13G/A
Feb 14, 2024	alyeska investment group, l.p.	9.99%	7,715,197	SC 13G/A
Feb 14, 2024	perceptive advisors llc	5.9%	4,580,249	SC 13G/A
Feb 14, 2024	orbimed advisors llc	0.0%	0	SC 13G/A
Feb 14, 2024	alexandria real estate equities, inc.	15.4%	12,859,054	SC 13G/A
Feb 13, 2024	vestal point capital, lp	5.4%	4,155,000	SC 13G

Recent SEC filings of Applied Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	144	Notice of Insider Sale Intent
May 16, 2024	144	Notice of Insider Sale Intent
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 25, 2024	EFFECT	EFFECT
Apr 25, 2024	424B3	Prospectus Filed
Apr 22, 2024	DEFA14A	DEFA14A
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	ARS	ARS
Apr 15, 2024	3	Insider Trading

Peers (Alternatives to Applied Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Applied Therapeutics Inc News

Latest updates

Applied Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Revenue	-	-	-	-	-	10,660
Operating Expenses	4.6%	21,283	20,340	15,495	17,176	21,518
S&GA Expenses	-100.0%	-	5,038	4,710	5,293	5,583
R&D Expenses	-20.2%	12,217	15,303	10,785	11,883	15,935
Net Income	-122.8%	-83,938	-37,679	-42,370	-29,577	-10,137
Net Income Margin	-61.6%	-19.37*	-11.98*	-	-	-
Free Cashflow	-11.2%	-18,911	-17,005	-14,726	-16,452	-6,990

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	175.8%	151	55.00	45.00	44.00	30.00	38.00	57.00	78.00	65.00	90.00	119	137	156	105	125	151	166	48.00	37.00	47.00	17.00
Current Assets	177.5%	151	54.00	44.00	43.00	29.00	37.00	56.00	77.00	64.00	88.00	117	135	154	103	123	149	164	46.00	37.00	47.00	17.00
Cash Equivalents	193.6%	146	50.00	37.00	36.00	23.00	17.00	40.00	56.00	38.00	54.00	70.00	78.00	84.00	57.00	49.00	101	93.00	19.00	13.00	41.00	15.00
Liabilities	16.6%	84.00	72.00	56.00	48.00	34.00	34.00	47.00	52.00	23.00	27.00	32.00	25.00	21.00	23.00	22.00	20.00	10.00	16.00	7.00	7.00	6.00
Current Liabilities	17.9%	84.00	71.00	56.00	47.00	33.00	33.00	47.00	52.00	22.00	26.00	31.00	23.00	20.00	21.00	21.00	19.00	8.00	14.00	7.00	7.00	6.00
Shareholder's Equity	492.5%	67.00	-17.15	-	-	-4.07	4.00	10.00	26.00	42.00	63.00	87.00	112	135	82.00	103	130	156	33.00	31.00	40.00	-
Retained Earnings	-17.9%	-552	-468	-430	-388	-358	-348	-334	-315	-289	-266	-239	-210	-184	-160	-137	-107	-79.14	-66.77	-49.14	-38.42	-29.99
Additional Paid-In Capital	37.3%	620	451	420	384	355	353	344	341	331	329	326	323	320	243	240	237	235	99.00	80.00	78.00	2.00
Shares Outstanding	34.6%	114	85.00	77.00	62.00	48.00	48.00	34.00	27.00	26.00	26.00	25.00	26.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	64.00	-	-	-	28.00	-	-	-	393	-	-	-	659	-	-	-	68.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-11.2%	-18,911	-17,005	-14,726	-16,452	-6,990	-15,893	-19,390	-18,400	-24,410	-26,942	-15,665	-25,908	-22,213	-22,750	-20,693	-15,911	-18,855	-12,407	-7,839	-9,059	-7,002
Share Based Compensation	46.3%	2,379	1,626	1,836	1,843	2,055	1,998	3,297	2,231	2,077	2,849	2,645	2,702	2,981	2,555	2,403	1,737	1,331	1,348	1,219	3,279	325
Cashflow From Investing	-	-	-	-	-	13,872	-6,905	5,021	5,529	9,525	11,807	8,518	16,780	-24,672	28,444	-30,246	24,044	-41,711	-	-	-	-
Cashflow From Financing	292.2%	115,497	29,446	16,567	29,151	-622	-933	-971	30,385	-789	-1,184	-1,080	3,495	73,486	3,093	-1,236	218	134,219	18,320	-294	35,449	2,940

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

APLT Income Statement

2024-03-31

Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended
Condensed Statements of Operations - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
REVENUE:
Total revenue	$ 190	$ 10,660
COSTS AND EXPENSES:
Research and development	12,217	15,935
General and administrative	9,066	5,583
Total costs and expenses	21,283	21,518
LOSS FROM OPERATIONS	(21,093)	(10,858)
OTHER (EXPENSE) INCOME, NET:
Interest income	586	221
Change in fair value of warrant liabilities	(63,405)	469
Other expense	(26)	31
Total other (expense) income, net	(62,845)	721
Net loss	$ (83,938)	$ (10,137)
Net loss per share attributable to common stockholders-basic (in dollars per share)	$ (0.67)	$ (0.18)
Net loss per share attributable to common stockholders-diluted (in dollars per share)	$ (0.67)	$ (0.18)
Weighted-average common stock outstanding-basic (in shares)	125,318,993	56,357,983
Weighted-average common stock outstanding-diluted (in shares)	125,318,993	56,357,983
License
REVENUE:
Total revenue		$ 10,660
Research and development services
REVENUE:
Total revenue	$ 190

APLT Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 146,484	$ 49,898
Security deposits and leasehold improvements	253	254
Prepaid expenses and other current assets	4,169	4,234
Total current assets	150,906	54,386
Operating lease right-of-use asset	328	447
TOTAL ASSETS	151,234	54,833
CURRENT LIABILITIES:
Current portion of operating lease liabilities	308	429
Accounts payable	4,019	1,742
Accrued expenses and other current liabilities	14,641	15,286
Warrant liabilities	64,937	53,725
Total current liabilities	83,905	71,182
NONCURRENT LIABILITIES:
Noncurrent portion of operating lease liabilities	35	38
Clinical holdback - long-term portion		759
Total noncurrent liabilities	35	797
Total liabilities	83,940	71,979
STOCKHOLDERS' EQUITY/(DEFICIT):
Common stock, $0.0001 par value; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 114,241,803 shares issued and outstanding as of March 31, 2024 and 84,869,832 shares issued and outstanding as of December 31, 2023	11	8
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023
Additional paid-in capital	619,807	451,432
Accumulated deficit	(552,524)	(468,586)
Total stockholders' (deficit)/equity	67,294	(17,146)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT)	$ 151,234	$ 54,833

About Applied Therapeutics Inc

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

CEO	Dr. Shoshana Shendelman Ph.D.
WEBSITE	appliedtherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	22

Applied Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Applied Therapeutics Inc? What does APLT stand for in stocks?

APLT is the stock ticker symbol of Applied Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Applied Therapeutics Inc (APLT)?

As of Fri May 17 2024, market cap of Applied Therapeutics Inc is 477.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APLT stock?

You can check APLT's fair value in chart for subscribers.

What is the fair value of APLT stock?

You can check APLT's fair value in chart for subscribers. The fair value of Applied Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Applied Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APLT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Applied Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APLT is over valued or under valued. Whether Applied Therapeutics Inc is cheap or expensive depends on the assumptions which impact Applied Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APLT.

What is Applied Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, APLT's PE ratio (Price to Earnings) is -2.47 and Price to Sales (PS) ratio is 47.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APLT PE ratio will change depending on the future growth rate expectations of investors.